Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
- 26 September 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (13), 2286-2288
- https://doi.org/10.1182/blood-2013-07-512442
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsLeukemia, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database MergeJournal of Clinical Oncology, 2012
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of lifeBritish Journal of Haematology, 2003